[1] J L GOLDSTEIN. Receptor-mediated endocytosis: concepts emerging from the LDL receptor system.[J]. Annual review of cell biology, 1985, 1: 1-39. DOI:
10.1146/annurev.cb.01.110185.000245[2] M J RUDLING. Low density lipoprotein receptor-binding activity in human tissues: quantitative importance of hepatic receptors and evidence for regulation of their expression in vivo.[J]. Proceedings of the National Academy of Sciences of the United States of America, 1990, 87 9: 3469-3473. DOI:
10.1073/pnas.87.9.3469[3] SUZANNE BENJANNET. NARC-1/PCSK9 and its natural mutants: zymogen cleavage and effects on the low density lipoprotein (LDL) receptor and LDL cholesterol.[J]. The Journal of Biological Chemistry, 2004, 279 47: 48865-48875. DOI:
10.1074/jbc.m409699200[4] D. PRATICò. Acceleration of atherogenesis by COX-1-dependent prostanoid formation in low density lipoprotein receptor knockout mice[J]. Proceedings of the National Academy of Sciences of the United States of America, 2001, 98 1: 3358-3363. DOI:
10.1073/pnas.061607398[5] MELISSA A AUSTIN. Genetic causes of monogenic heterozygous familial hypercholesterolemia: a HuGE prevalence review.[J]. American journal of epidemiology, 2004, 160 5: 407-420. DOI:
10.1093/aje/kwh236[6] AURéLIEN J C POMMIER. Liver x receptors protect from development of prostatic intra-epithelial neoplasia in mice.[J]. PLoS Genetics, 2013, 9 5: e1003483. DOI:
10.1371/journal.pgen.1003483[7] CYNTHIA HONG. The E3 ubiquitin ligase IDOL induces the degradation of the low density lipoprotein receptor family members VLDLR and ApoER2.[J]. The Journal of Biological Chemistry, 2010: 19720-19726. DOI:
10.1074/jbc.m110.123729